Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive-compulsive disorder: A systematic review and meta-analysis of randomized clinical trials
[DOI] [PubMed] [Google Scholar] 77.Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, West DW, Hankin J, Teh CZ, Dreon DM, Paffenbarger RS., Jr Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada
Cagrilintide Dose Escalation Studies Phase 2 trials evaluated multiple cagrilintide doses to identify the optimal balance between efficacy and tolerability: 0.3 mg weekly Minimal efficacy, excellent tolerability 0.6 mg weekly Moderate effects, good tolerability 1.2 mg weekly Strong efficacy, acceptable side effects 2.4 mg weekly Optimal efficacy-tolerability balance 4.5 mg weekly Excessive GI side effects outweighed benefits The 2.4 mg weekly dose emerged as the standard in phase 3 trials, providing substantial metabolic benefits while maintaining an acceptable side effect profile[6]
It is also explored for its potential role in supporting growth hormone activity and reducing oxidative stress in neural tissue
FAQs Can Melanotan-2 and PT-141 be used together in the same research protocol
